Macquarie initiates coverage on Mankind Pharma, sees 30% upside
Mankind Pharma derives 98% of its revenue from the domestic pharma market. Within its domestic business, 90% of its revenue comes from prescription pharmaceuticals and the rest from the consumer health business.
